NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with Amgen to develop a diagnostic test for a drug candidate for treating a rare and deadly form of cancer.
The company did not specify the type of cancer Amgen will target in this collaboration.
"Our agreement with Amgen is one of several partnerships that Dako has entered with pharma companies to enable the development of diagnostic tests to predict which patients are most likely to respond to specific treatments," Dako CEO Lars Holmkvist said in a statement.
The company has struck similar agreements over the past two years with AstraZeneca, Bristol-Myers Squibb, and Genentech.